Sano Genetics EIS

Clinical trials heavily rely on recruiting patients based on very selective inclusion/exclusion criteria – particularly for precision medicine – and keeping them engaged.

However, current patient recruitment methods tend to be slow, manual and fragmented, with patient data spread across disconnected healthcare providers, laboratories and record systems.

Roughly half of all clinical trials face severe delays due to recruitment issues, and up to 85% fail to retain enough participants. Given a $55,000 typical daily cost of running a Phase III trial, such delays can translate into tens of millions of dollars’ worth of lost time.

Sano has created a digital platform and database that simplifies and speeds up how clinical trials can recruit and retain patient-participants.

The Company reports its platform can deliver patient recruitment up to five times faster than traditional approaches by combining digital patient-finding, genetic testing, medical record analysis and participant engagement in a single system.

In addition, Sano is building a patient data ‘system of record’ – an authoritative data repository that unifies patient data collected from trials, medical record retrieval services, and multiple other sources. This helps match individuals to trials more quickly and with better accuracy.

Sano’s system also captures longitudinal data – information collected over a prolonged period – to help pharmaceutical companies generate a clearer view of treatment outcomes over time.

Another notable feature is the Virtual Waiting Room. This is where patients can track test kit delivery and next steps, access a library of educational content, and receive updates relevant to the trial. According to Sano, keeping participants engaged helps deliver stronger retention, richer data and more predictable timelines for clinical trials. It also creates a pre-qualified eligible, educated, and interested patient pool for current and future studies.

Globally the clinical trials industry is worth an estimated $70.7 billion, expected to double to $144.4 billion by 2035.

Launched in 2017, Sano operates in the UK, US, Australia and the Netherlands with a combined technology and services model. It charges its pharmaceutical, biotech and population health clients a subscription; for patients, the platform is free to use. Sano also powers clients’ branded portals for participant recruitment and engagement, nationally and globally.

Sano reports strong commercial traction. It has eight large-pharma customers, including AstraZeneca, Eli Lilly, Astellas and Insmed. The Company reports it recently signed its fourth contract with Eli Lilly, and a separate contract with a top-10 pharma customer was signed in 2025. The contract is worth $4.6 million for a single trial and potentially up to $20 million a year if expanded to more trials.

The Company reports gross margins are consistently above 80%, its patient database has grown to over 63,000 consented patients, and average pharma annual contract value is up from £140k to £353k.

The business is backed by investors including Innovate UK, MMC Ventures, Plural and Seedcamp. MMC first invested in March 2022, leading Sano’s $11 million Series A round.

Sano generated £3.5 million of revenue in the last 12 months and is targeting profitability by 2027 – not guaranteed.

Sano’s three co-founders met during their PhDs at Cambridge.

The current investment forms part of a £3.0 million round, following a £2.7 million fundraise completed in February 2026, led by Plural and MMC at a £40 million pre-money valuation. Wealth Club investors can co-invest on the same terms – there is an exclusive £350k allocation. The minimum investment is £20,301.40 and you can apply online.

If successful, the current funding round could unlock a £700k Innovate UK matched-funding grant, which would add non-dilutive capital.

The Company believes the current raise could support the business through to profitability, expected in late 2026 or early 2027. The target return, based on the Company’s forecasts, is 5x before EIS tax relief – high risk and not guaranteed.

This is a single company offer with no diversification. It involves investing in an early-stage, loss-making business, which is by nature high risk and prone to failure. There is a risk that the capital raised may not be sufficient to achieve the Company’s objectives. You could lose all the amount you invest.

Like all investments available through Wealth Club, it is only for experienced investors happy to make their own investment decisions without advice.

There is no ready market for unlisted EIS shares: they are illiquid and hard to sell and value. There will need to be an exit for you to receive a realised return on your investment. Exits are likely to take considerably longer than the three-year minimum EIS holding period; equally, an exit within three years could impact tax relief.

To claim tax relief, you will need an EIS3 certificate, normally issued once shares have been allotted. This can take several months: please check the deployment timescales carefully. Tax reliefs depend on company maintaining its EIS-qualifying status. Remember, tax rules can change and benefits depend on circumstances. Before you invest, please carefully read the Information Memorandum which contains further details on the considerable risks – alongside the Wealth Club Risks and Commitments.

Investors will subscribe directly for shares in Sano Genetics Limited. Shares issued in this round are expected to be EIS-qualifying – not guaranteed. The share price is £11.265971, implying a pre-money valuation of approximately £40 million.

An initial charge of 6% will be deducted from each investment at the point of subscription. EIS tax relief will be available on the subscription amount net of the initial charge. Wealth Club will be entitled to a performance fee on exit.

Wealth Club investors will invest using a nominee structure. This service is provided by Wealth Club’s subsidiary companies Wealth Club Asset Management Limited (authorised and regulated by the FCA) and Wealth Club Nominees Limited. Wealth Club Nominees Ltd will be completing the share subscription documentation on investors’ behalf.

Wealth Club investors will invest using a nominee structure. This service is provided by Wealth Club’s subsidiary companies Wealth Club Asset Management Limited (authorised and regulated by the FCA) and Wealth Club Nominees Limited. Wealth Club Nominees Ltd will be completing the share subscription documentation on investors’ behalf.

Please refer to the Schedule of Charges or more details on charges (may vary for different rounds). All the services Wealth Club and, where applicable, its subsidiaries provide are governed by the Terms and Conditions of the Wealth Club Services.

This financial promotion has been communicated and approved by Wealth Club Ltd on 9 June 2026

Wealth Club aims to make it easier for experienced investors to find information on – and apply for – investments. You should base your investment decision on the offer documents and ensure you have read and fully understand them before investing. The information on this webpage is a marketing communication. It is not advice or a personal or research recommendation to buy any of the investments mentioned, nor does it include any opinion as to the present or future value or price of these investments. It does not satisfy legal requirements promoting investment research independence and is thus not subject to prohibitions on dealing ahead of its dissemination.